Please use this identifier to cite or link to this item:
Title: Safinamide - a unique treatment targeting both dopaminergic and non-dopaminergic systems
Author: Kulisevsky Bojarski, Jaume
Others: Universitat Oberta de Catalunya (UOC)
Keywords: dopamine
Parkinson's disease
Issue Date: 4-Oct-2016
Publisher: European Neurological Review
Citation: Kulisevsky, J. (2016). Safinamide - a unique treatment targeting both dopaminergic and non-dopaminergic systems. European Neurological Review, 11(2), 101-105. doi: 10.17925/ENR.2016.11.02.101
Also see:
Abstract: Dopaminergic replacement therapies are prescribed widely to improve motor problems in Parkinson's disease (PD). However, as the disease progresses, the response to levodopa (l-dopa) doses becomes shorter and patients experience symptom recurrence at the end of the dose effect. These so-called OFF periods may become refractory to treatment, and may become associated with disabling motor fluctuations or dyskinesias. In addition to dopamine, glutamate excitotoxicity, resulting from disturbance of the homeostatic balance of neurotransmitters and elevated extracellular levels of glutamate, is potentially an important therapeutic target. Safinamide has been investigated in phase III clinical trials as adjunct therapy to l-dopa in mid- to late-stage fluctuating PD. Adding safinamide to l-dopa increases the time patients' symptoms are controlled so-called ON time, without increasing troublesome dyskinesia. Although safinamide has dopaminergic actions, recent data have suggested that the long-term effects of safinamide on dyskinesia are related to safinamide state- and use-dependent inhibition of sodium channels and stimulated glutamate release, rather than reduced dopaminergic stimulation. Safinamide's unique dual mechanism of action makes it a valuable treatment option for fluctuating PD patients.
Language: English
ISSN: 1758-3837
Appears in Collections:Articles

Files in This Item:
File Description SizeFormat 
Safinamide.pdf2.79 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons